CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: PBLD (ImmuneEditome ID:64081)

1. Gene summary of enriched editing regions for PBLD

check button Gene summary
Gene informationGene symbol

PBLD

Gene ID

64081

GeneSynonymsHEL-S-306|MAWBP|MAWDBP
GeneCytomap

10q21.3

GeneTypeprotein-coding
GeneDescriptionphenazine biosynthesis-like domain-containing protein|MAWD-binding protein|epididymis secretory protein Li 306|epididymis secretory sperm binding protein
GeneModificationdate20230517
UniprotIDP30039;A0A0C4DFS0
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr10:68283072-68284098:-ENST00000468798.4ENSG00000108187.14PBLDexonicAluSx,FLAM_C,(TG)nchr10:68283072-68284098:-.alignment
chr10:68285702-68288075:-ENST00000277795.7ENSG00000108187.14PBLDncRNA_exonicAluJr4,AluJb,AluSq2,AluSz,MER81,(AAAC)n,AluSx1chr10:68285702-68288075:-.alignment


Top

2. Tumor-specific enriched editing regions for PBLD


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr10:68285702-68288075:-KIRCEER2.1898e-02image
chr10:68285702-68288075:-KIRPEER8.8309e-04image
ENSG00000108187.14,PBLDKIRPEAG1.1077e-04image
chr10:68285702-68288075:-LIHCEER2.8870e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000108187.14,PBLDKIRCPathEAG4.8192e-023.1347e-02-0.1109image
chr10:68283072-68284098:-KIRPCliEER2.0513e-052.1894e-030.3762image
chr10:68285702-68288075:-OVCliEER2.2788e-028.4417e-03-0.5149image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr10:68283072-68284098:-ESCAEER4.3473e-031.7972e-021.9364e+03image

Top

3. Enriched editing regions and immune related genes for PBLD


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for PBLD


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

5. Enriched editing regions and immune infiltration for PBLD


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr10:68283072-68284098:-ACCEERNeutrophils1.0326e-030.4780image
ENSG00000108187.14,PBLDACCEAGNeutrophils1.4393e-030.4610image
ENSG00000108187.14,PBLDBLCAEAGNK_cells_activated2.0244e-020.2695image
chr10:68283072-68284098:-BRCAEERB_cells_memory6.8356e-030.1043image
ENSG00000108187.14,PBLDBRCAEAGB_cells_memory8.5707e-030.1014image
ENSG00000108187.14,PBLDCESCEAGT_cells_regulatory_(Tregs)3.8146e-030.5203image
chr10:68283072-68284098:-COADEERMast_cells_activated6.3527e-040.4068image
chr10:68285702-68288075:-COADEERT_cells_CD83.6750e-020.4475image
chr10:68283072-68284098:-ESCAEERT_cells_CD4_memory_resting4.3279e-03-0.3197image
chr10:68285702-68288075:-ESCAEERNK_cells_activated4.0929e-020.2994image
ENSG00000108187.14,PBLDESCAEAGT_cells_CD4_memory_activated8.4504e-03-0.2674image
ENSG00000108187.14,PBLDGBMEAGNeutrophils1.5211e-02-0.2471image
ENSG00000108187.14,PBLDHNSCEAGB_cells_naive5.0777e-03-0.5878image
chr10:68283072-68284098:-KIRCEERNeutrophils2.0152e-020.2193image
chr10:68285702-68288075:-KIRCEERPlasma_cells1.1429e-020.1759image
ENSG00000108187.14,PBLDKIRCEAGT_cells_regulatory_(Tregs)2.8243e-02-0.1350image
chr10:68283072-68284098:-KIRPEERNK_cells_resting1.4882e-060.4421image
ENSG00000108187.14,PBLDKIRPEAGMonocytes2.2888e-020.1739image
chr10:68283072-68284098:-LGGEERT_cells_follicular_helper6.7210e-030.1280image
ENSG00000108187.14,PBLDLGGEAGT_cells_follicular_helper5.8310e-030.1302image
ENSG00000108187.14,PBLDLIHCEAGT_cells_regulatory_(Tregs)3.3931e-02-0.1381image
chr10:68285702-68288075:-LUADEEREosinophils9.1422e-030.4228image
ENSG00000108187.14,PBLDLUADEAGMacrophages_M23.9555e-02-0.1619image
ENSG00000108187.14,PBLDLUSCEAGMacrophages_M23.5100e-02-0.2541image
chr10:68285702-68288075:-OVEERT_cells_follicular_helper1.5560e-020.5205image
ENSG00000108187.14,PBLDOVEAGT_cells_CD4_naive2.2368e-120.4864image
chr10:68283072-68284098:-PAADEERT_cells_CD4_memory_resting4.1837e-03-0.3560image
chr10:68283072-68284098:-PCPGEERDendritic_cells_activated3.2793e-050.4084image
ENSG00000108187.14,PBLDPCPGEAGDendritic_cells_activated3.2793e-050.4084image
chr10:68283072-68284098:-PRADEERMacrophages_M01.3588e-02-0.1335image
ENSG00000108187.14,PBLDPRADEAGMacrophages_M06.5516e-03-0.1459image
ENSG00000108187.14,PBLDREADEAGDendritic_cells_resting5.1361e-060.7867image
chr10:68283072-68284098:-STADEERMacrophages_M24.9313e-020.1484image
chr10:68285702-68288075:-STADEERT_cells_CD87.5566e-030.1938image
ENSG00000108187.14,PBLDSTADEAGT_cells_regulatory_(Tregs)3.6625e-020.1245image
chr10:68283072-68284098:-THCAEERMast_cells_activated2.3936e-030.2446image
ENSG00000108187.14,PBLDTHCAEAGMast_cells_activated2.3936e-030.2446image
ENSG00000108187.14,PBLDUCECEAGT_cells_regulatory_(Tregs)5.1766e-030.3655image


Top

6. Enriched editing regions and immune gene sets for PBLD


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr10:68283072-68284098:-STADEER4.7821e-04image1.7028e-020.1797image
ENSG00000108187.14,PBLDSTADEAG3.8248e-02image3.7086e-02-0.1242image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000108187.14,PBLDOVEAG3.5048e-02-0.15511.6554e-02-0.17603.2333e-03-0.21541.7877e-02-0.1740image
chr10:68285702-68288075:-STADEER3.6636e-030.21043.8071e-020.15101.6102e-020.17493.5004e-040.2574image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr10:68283072-68284098:-ACCGSVA_HALLMARK_PEROXISOMEEER1.6278e-02-0.3603image
ENSG00000108187.14,PBLDACCGSVA_HALLMARK_PEROXISOMEEAG2.3682e-02-0.3368image
ENSG00000108187.14,PBLDBLCAGSVA_HALLMARK_PEROXISOMEEAG1.7579e-02-0.2753image
chr10:68283072-68284098:-BRCAGSVA_HALLMARK_PROTEIN_SECRETIONEER2.3088e-05-0.1626image
ENSG00000108187.14,PBLDBRCAGSVA_HALLMARK_PROTEIN_SECRETIONEAG5.0958e-05-0.1557image
ENSG00000108187.14,PBLDCESCGSVA_HALLMARK_MYOGENESISEAG3.0681e-03-0.5306image
chr10:68283072-68284098:-COADGSVA_HALLMARK_BILE_ACID_METABOLISMEER8.6344e-07-0.5594image
ENSG00000108187.14,PBLDCOADGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG2.5427e-02-0.2424image
chr10:68285702-68288075:-COADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER2.7357e-030.6071image
chr10:68285702-68288075:-ESCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.5682e-020.3253image
chr10:68283072-68284098:-ESCAGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER2.4703e-04-0.4037image
ENSG00000108187.14,PBLDESCAGSVA_HALLMARK_APICAL_JUNCTIONEAG9.1839e-05-0.3885image
ENSG00000108187.14,PBLDGBMGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG1.3512e-020.2513image
ENSG00000108187.14,PBLDHNSCGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG5.1243e-030.5873image
chr10:68283072-68284098:-KICHGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER9.9804e-03-0.4183image
ENSG00000108187.14,PBLDKICHGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG9.9804e-03-0.4183image
chr10:68285702-68288075:-KIRCGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER1.9480e-060.3245image
ENSG00000108187.14,PBLDKIRCGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG1.1140e-040.2356image
chr10:68283072-68284098:-KIRCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER3.5584e-02-0.1988image
ENSG00000108187.14,PBLDKIRPGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG1.7804e-04-0.2828image
chr10:68283072-68284098:-KIRPGSVA_HALLMARK_HEME_METABOLISMEER4.4260e-03-0.2706image
chr10:68283072-68284098:-LGGGSVA_HALLMARK_BILE_ACID_METABOLISMEER2.9150e-04-0.1706image
ENSG00000108187.14,PBLDLGGGSVA_HALLMARK_BILE_ACID_METABOLISMEAG1.9351e-04-0.1754image
chr10:68285702-68288075:-LIHCGSVA_HALLMARK_PROTEIN_SECRETIONEER1.0259e-020.2012image
ENSG00000108187.14,PBLDLIHCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.6762e-04-0.2426image
ENSG00000108187.14,PBLDLUADGSVA_HALLMARK_HEME_METABOLISMEAG3.4055e-04-0.2780image
chr10:68283072-68284098:-LUADGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER4.7096e-030.2393image
ENSG00000108187.14,PBLDLUSCGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG2.4972e-020.2698image
chr10:68283072-68284098:-LUSCGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER1.1097e-020.3062image
ENSG00000108187.14,PBLDMESOGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG1.6123e-040.7321image
ENSG00000108187.14,PBLDOVGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.4637e-05-0.3127image
chr10:68285702-68288075:-OVGSVA_HALLMARK_PANCREAS_BETA_CELLSEER4.7061e-02-0.4380image
chr10:68283072-68284098:-PAADGSVA_HALLMARK_MYC_TARGETS_V1EER7.2028e-040.4150image
ENSG00000108187.14,PBLDPAADGSVA_HALLMARK_ANGIOGENESISEAG1.2713e-05-0.4778image
ENSG00000108187.14,PBLDPCPGGSVA_HALLMARK_KRAS_SIGNALING_DNEAG5.8022e-03-0.2782image
chr10:68283072-68284098:-PCPGGSVA_HALLMARK_KRAS_SIGNALING_DNEER5.8022e-03-0.2782image
chr10:68283072-68284098:-PRADGSVA_HALLMARK_MTORC1_SIGNALINGEER1.7892e-04-0.2016image
ENSG00000108187.14,PBLDPRADGSVA_HALLMARK_MTORC1_SIGNALINGEAG1.1739e-05-0.2332image
ENSG00000108187.14,PBLDSKCMGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG2.5267e-02-0.3725image
chr10:68283072-68284098:-STADGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER1.7028e-020.1797image
chr10:68285702-68288075:-STADGSVA_HALLMARK_UV_RESPONSE_UPEER3.9777e-060.3283image
ENSG00000108187.14,PBLDSTADGSVA_HALLMARK_HYPOXIAEAG7.9798e-03-0.1577image
ENSG00000108187.14,PBLDUCECGSVA_HALLMARK_ANDROGEN_RESPONSEEAG6.6256e-04-0.4377image


Top

7. Enriched editing regions and drugs for PBLD


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr10:68283072-68284098:-ACCAZD6244EER1.1484e-02-0.3777image
ENSG00000108187.14,PBLDACCAZD6244EAG1.6727e-02-0.3550image
ENSG00000108187.14,PBLDBLCADocetaxelEAG8.3141e-05-0.4413image
chr10:68283072-68284098:-BRCAGDC.0449EER8.5436e-07-0.1887image
ENSG00000108187.14,PBLDBRCAGDC.0449EAG1.9654e-06-0.1824image
ENSG00000108187.14,PBLDCESCKIN001.135EAG4.7206e-030.5099image
ENSG00000108187.14,PBLDCOADBIBW2992EAG2.1953e-02-0.2498image
chr10:68285702-68288075:-COADKU.55933EER1.0458e-02-0.5341image
chr10:68283072-68284098:-COADBortezomibEER6.0860e-030.3318image
chr10:68283072-68284098:-ESCAJNK.Inhibitor.VIIIEER4.4048e-06-0.4935image
ENSG00000108187.14,PBLDESCAJNJ.26854165EAG5.6433e-040.3473image
chr10:68285702-68288075:-ESCAAG.014699EER1.8846e-020.3414image
ENSG00000108187.14,PBLDGBMJNK.Inhibitor.VIIIEAG5.6670e-030.2803image
ENSG00000108187.14,PBLDHNSCCMKEAG1.5581e-02-0.5204image
chr10:68283072-68284098:-KICHA.443654EER6.0037e-04-0.5376image
ENSG00000108187.14,PBLDKICHA.443654EAG6.0037e-04-0.5376image
ENSG00000108187.14,PBLDKIRCFH535EAG9.1511e-03-0.1601image
chr10:68285702-68288075:-KIRCBexaroteneEER7.0463e-04-0.2342image
chr10:68283072-68284098:-KIRCGDC0941EER1.1724e-030.3042image
chr10:68283072-68284098:-KIRPAS601245EER5.0160e-050.3782image
ENSG00000108187.14,PBLDKIRPBicalutamideEAG9.5400e-040.2504image
ENSG00000108187.14,PBLDLGGBI.D1870EAG2.5036e-04-0.1724image
chr10:68283072-68284098:-LGGBI.D1870EER2.7570e-04-0.1712image
ENSG00000108187.14,PBLDLIHCA.770041EAG3.1273e-040.2458image
chr10:68285702-68288075:-LIHCImatinibEER6.2753e-04-0.2659image
chr10:68283072-68284098:-LUADAP.24534EER5.2286e-03-0.2365image
ENSG00000108187.14,PBLDLUADLapatinibEAG1.7388e-030.2442image
chr10:68285702-68288075:-LUADA.770041EER2.0680e-02-0.3791image
chr10:68283072-68284098:-LUSCBexaroteneEER6.7867e-03-0.3253image
ENSG00000108187.14,PBLDLUSCBexaroteneEAG3.8114e-02-0.2502image
ENSG00000108187.14,PBLDMESOMG.132EAG6.1415e-03-0.5773image
ENSG00000108187.14,PBLDOVAZD6482EAG5.2126e-030.2052image
chr10:68285702-68288075:-OVFH535EER2.1911e-03-0.6303image
chr10:68283072-68284098:-PAADFTI.277EER7.3441e-04-0.4144image
ENSG00000108187.14,PBLDPAADABT.263EAG2.1558e-030.3489image
ENSG00000108187.14,PBLDPCPGAKT.inhibitor.VIIIEAG1.1521e-020.2556image
chr10:68283072-68284098:-PCPGAKT.inhibitor.VIIIEER1.1521e-020.2556image
chr10:68283072-68284098:-PRADDasatinibEER4.0688e-04-0.1921image
ENSG00000108187.14,PBLDPRADAP.24534EAG2.2505e-03-0.1637image
ENSG00000108187.14,PBLDREADATRAEAG2.6101e-02-0.4533image
chr10:68283072-68284098:-SARCIPA.3EER3.6112e-020.3457image
ENSG00000108187.14,PBLDSARCIPA.3EAG3.6112e-020.3457image
ENSG00000108187.14,PBLDSKCMLapatinibEAG4.2276e-020.3403image
chr10:68285702-68288075:-STADAMG.706EER4.7749e-03-0.2050image
chr10:68283072-68284098:-STADAP.24534EER1.4194e-05-0.3208image
ENSG00000108187.14,PBLDSTADBleomycinEAG2.5807e-040.2160image
ENSG00000108187.14,PBLDTHCABMS.536924EAG2.5825e-020.1814image
chr10:68283072-68284098:-THCABMS.536924EER2.5825e-020.1814image
ENSG00000108187.14,PBLDUCECAZD6244EAG2.7374e-08-0.6576image
chr10:68283072-68284098:-UCECGDC.0449EER2.1788e-04-0.4912image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType